No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 694 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR ¿Qué es la escasez de medicamentos y cómo puede afectar a... June 30, 2023 Do as I say, not as I do – when the... July 13, 2021 Trastuzumab Deruxtecan Shows Promising Activity Among Patients with HER2-positive and Signal... September 2, 2024 OncoArray Links Dozens of DNA Variants to Risk for Common Cancers June 12, 2018 Load more HOT NEWS Withdrawal of the Application to Change the EMA Marketing Authorisation for... How Can Occupational Therapy Assist with Chemotherapy-induced Peripheral Neuropathy? ¿Qué deben saber las personas con cáncer sobre el consumo de... Young Women with Breast Cancer Often Forgo Hormone Therapy Due to...
